Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PHM.MCthis companyPharma Mar, S.A.	€67.30	17.42×	5.12×	5.82×	27.34×	-26.6%	94.5%	18.2%	33.9%	29.8%	12.8%	3.4%	0.2×	0.65×	16.38×	3.02×	1.1%	8	6.88	4	A-
ALM.MCAlmirall, S.A.	€10.52	58.36×	1.85×	2.49×	12.62×	30.9%	41.2%	6.1%	4.2%	3.1%	2.1%	4.9%	0.23×	0.02×	3.79×	2.04×	0.9%	7	2.93	3	B+
ATRY.MCAtrys Health, S.A.	€2.65	-2.22×	1.47×	1.58×	-46.9×	-255.2%	43.5%	-6.4%	-71.1%	-66.0%	-2.1%	-6.3%	1.7×	-24.57×	-0.47×	0.81×	0.0%	3	-0.45	1	C-
BST.MCBiotechnologies Assets S.A.	€0.21	-7.42×	2.31×	4.61×	138.37×	-110.4%	-16.6%	-61.6%	-62.0%	-31.0%	-16.8%	-0.1%	0.28×	11.74×	-11.17×	1.4×	0.0%	4	-1.34	1	C-
CBAV.MCClínica Baviera, S.A.	€52.00	18.9×	7.52×	2.74×	8.39×	-33.0%	42.1%	27.3%	13.9%	38.2%	29.5%	5.6%	0.63×	0.6×	36.05×	0.96×	3.2%	5	5.81	4	A-
FAE.MCFaes Farma, S.A.	€4.92	19.85×	2.16×	2.63×	18.65×	-29.6%	37.4%	11.9%	13.0%	10.7%	5.7%	3.9%	0.55×	2.87×	11.51×	2.61×	3.5%	5	2.82	4	A
Peer median	—	18.9×	2.16×	2.63×	12.62×	-33.0%	41.2%	6.1%	4.2%	3.1%	2.1%	3.9%	0.55×	0.6×	3.79×	1.4×	0.9%	5	2.82	3	—